tiprankstipranks
Kura Oncology (KURA)
NASDAQ:KURA
US Market
KURA
Kura Oncology
RESEARCH TOOLSreports
Want to see KURA full AI Analyst Report?

Kura Oncology (KURA) Stock Forecast & Price Target

888 Followers
See the Price Targets and Ratings of:

KURA Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Kura
Oncology
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

KURA Stock 12 Month Forecast

Average Price Target

$28.11
▲(190.40% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Kura Oncology in the last 3 months. The average price target is $28.11 with a high forecast of $40.00 and a low forecast of $15.00. The average price target represents a 190.40% change from the last price of $9.68.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","41":"$41","13.25":"$13.25","22.5":"$22.5","31.75":"$31.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.11111111111111,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,13.25,22.5,31.75,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.78,13.027692307692307,15.275384615384613,17.52307692307692,19.77076923076923,22.018461538461537,24.26615384615384,26.513846153846153,28.761538461538457,31.00923076923077,33.25692307692307,35.504615384615384,37.75230769230769,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.78,12.113162393162392,13.446324786324785,14.77948717948718,16.112649572649573,17.445811965811966,18.77897435897436,20.112136752136752,21.445299145299145,22.77846153846154,24.11162393162393,25.444786324786325,26.777948717948718,{"y":28.11111111111111,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.78,11.104615384615384,11.429230769230768,11.753846153846153,12.078461538461537,12.403076923076922,12.727692307692307,13.052307692307693,13.376923076923077,13.701538461538462,14.026153846153846,14.350769230769231,14.675384615384615,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.44,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.39,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.27,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.68,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.34,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.77,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.035,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.78,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$40.00Average Price Target$28.11Lowest Price Target$15.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on KURA
Salim Syed
Mizuho Securities
Mizuho Securities
$25
Buy
158.26%
Upside
Reiterated
06/23/26
Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA) and Corbus Pharmaceuticals (NASDAQ: CRBP)
Jefferies Analyst forecast on KURA
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$28
Buy
189.26%
Upside
Reiterated
06/15/26
Jefferies Sticks to Their Buy Rating for Kura Oncology (KURA)
H.C. Wainwright Analyst forecast on KURA
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
$40
Buy
313.22%
Upside
Reiterated
06/15/26
Analysts' Top Healthcare Picks: MBX Biosciences, Inc. (MBX), Kura Oncology (KURA)
LifeSci Capital Analyst forecast on KURA
Charles Zhu
LifeSci Capital
LifeSci Capital
$28
Buy
189.26%
Upside
Reiterated
06/15/26
Zhu Reiterates Buy on Ziftomenib Developer, Citing Strong Phase 1 AML Data and Favorable Safety Profile; Price Target Maintained at $28
Wedbush Analyst forecast on KURA
Robert Driscoll
Wedbush
Wedbush
$36
Buy
271.90%
Upside
Reiterated
06/15/26
Wedbush Remains a Buy on Kura Oncology (KURA)
Barclays Analyst forecast on KURA
Etzer Darout
Barclays
Barclays
$28
Buy
189.26%
Upside
Reiterated
06/04/26
Analysts' Top Healthcare Picks: Kura Oncology (KURA), Align Tech (ALGN)
Lake Street Analyst forecast on KURA
Daniel Brims
Lake Street
Lake Street
$23
Buy
137.60%
Upside
Initiated
06/04/26
Lake Street Initiates a Buy Rating on Kura Oncology (KURA)
Bank of America Securities Analyst forecast on KURA
Jason Zemansky
Bank of America Securities
Bank of America Securities
$30
Buy
209.92%
Upside
Reiterated
06/03/26
Bank of America Securities Sticks to Its Buy Rating for Kura Oncology (KURA)
UBS Analyst forecast on KURA
David Dai
UBS
UBS
$15
Buy
54.96%
Upside
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Sensei Biotherapeutics (NASDAQ: SNSE) and Kura Oncology (NASDAQ: KURA)
TD Cowen Analyst forecast on KURA
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA) and Maze Therapeutics, Inc. (NASDAQ: MAZE)
Guggenheim Analyst forecast on KURA
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
03/06/26
Kura Oncology (KURA) Receives a Hold from Guggenheim
Leerink Partners Analyst forecast on KURA
Jonathan Chang
Leerink Partners
Leerink Partners
$25→$20
Buy
106.61%
Upside
Reiterated
01/13/26
Kura Oncology (KURA) Receives a Buy from Leerink Partners
BTIG Analyst forecast on KURA
Justin Zelin
BTIG
BTIG
―
Hold
―
Reiterated
12/09/25
BTIG Sticks to Their Hold Rating for Kura Oncology (KURA)
Citizens JMP Analyst forecast on KURA
Reni Benjamin
Citizens JMP
Citizens JMP
$24
Buy
147.93%
Upside
Reiterated
09/30/25
Kura Oncology (KURA) Gets a Buy from Citizens JMP
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on KURA
Salim Syed
Mizuho Securities
Mizuho Securities
$25
Buy
158.26%
Upside
Reiterated
06/23/26
Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA) and Corbus Pharmaceuticals (NASDAQ: CRBP)
Jefferies Analyst forecast on KURA
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$28
Buy
189.26%
Upside
Reiterated
06/15/26
Jefferies Sticks to Their Buy Rating for Kura Oncology (KURA)
H.C. Wainwright Analyst forecast on KURA
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
$40
Buy
313.22%
Upside
Reiterated
06/15/26
Analysts' Top Healthcare Picks: MBX Biosciences, Inc. (MBX), Kura Oncology (KURA)
LifeSci Capital Analyst forecast on KURA
Charles Zhu
LifeSci Capital
LifeSci Capital
$28
Buy
189.26%
Upside
Reiterated
06/15/26
Zhu Reiterates Buy on Ziftomenib Developer, Citing Strong Phase 1 AML Data and Favorable Safety Profile; Price Target Maintained at $28
Wedbush Analyst forecast on KURA
Robert Driscoll
Wedbush
Wedbush
$36
Buy
271.90%
Upside
Reiterated
06/15/26
Wedbush Remains a Buy on Kura Oncology (KURA)
Barclays Analyst forecast on KURA
Etzer Darout
Barclays
Barclays
$28
Buy
189.26%
Upside
Reiterated
06/04/26
Analysts' Top Healthcare Picks: Kura Oncology (KURA), Align Tech (ALGN)
Lake Street Analyst forecast on KURA
Daniel Brims
Lake Street
Lake Street
$23
Buy
137.60%
Upside
Initiated
06/04/26
Lake Street Initiates a Buy Rating on Kura Oncology (KURA)
Bank of America Securities Analyst forecast on KURA
Jason Zemansky
Bank of America Securities
Bank of America Securities
$30
Buy
209.92%
Upside
Reiterated
06/03/26
Bank of America Securities Sticks to Its Buy Rating for Kura Oncology (KURA)
UBS Analyst forecast on KURA
David Dai
UBS
UBS
$15
Buy
54.96%
Upside
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Sensei Biotherapeutics (NASDAQ: SNSE) and Kura Oncology (NASDAQ: KURA)
TD Cowen Analyst forecast on KURA
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Kura Oncology (NASDAQ: KURA) and Maze Therapeutics, Inc. (NASDAQ: MAZE)
Guggenheim Analyst forecast on KURA
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
03/06/26
Kura Oncology (KURA) Receives a Hold from Guggenheim
Leerink Partners Analyst forecast on KURA
Jonathan Chang
Leerink Partners
Leerink Partners
$25→$20
Buy
106.61%
Upside
Reiterated
01/13/26
Kura Oncology (KURA) Receives a Buy from Leerink Partners
BTIG Analyst forecast on KURA
Justin Zelin
BTIG
BTIG
―
Hold
―
Reiterated
12/09/25
BTIG Sticks to Their Hold Rating for Kura Oncology (KURA)
Citizens JMP Analyst forecast on KURA
Reni Benjamin
Citizens JMP
Citizens JMP
$24
Buy
147.93%
Upside
Reiterated
09/30/25
Kura Oncology (KURA) Gets a Buy from Citizens JMP
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kura Oncology

3 Months
Robert DriscollWedbush
Success Rate
14/25 ratings generated profit
56%
Average Return
+11.89%
Copying Robert Driscoll's trades and holding each position for 3 Months would result in 56.00% of your transactions generating a profit, with an average return of +11.89% per trade.
1 Year
Jason ZemanskyBank of America Securities
Success Rate
18/26 ratings generated profit
69%
Average Return
+10.20%
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +10.20% per trade.
2 Years
Jason ZemanskyBank of America Securities
Success Rate
18/26 ratings generated profit
69%
Average Return
+5.70%
Copying Jason Zemansky's trades and holding each position for 2 Years would result in 69.23% of your transactions generating a profit, with an average return of +5.70% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KURA Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
16
16
25
32
27
Buy
2
1
2
1
1
Hold
1
1
1
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
18
28
33
28
In the current month, KURA has received 28 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. KURA average Analyst price target in the past 3 months is 28.11.
Each month's total comprises the sum of three months' worth of ratings.

KURA Financial Forecast

KURA Earnings Forecast

Next quarter’s earnings estimate for KURA is -$0.90 with a range of -$1.02 to -$0.81. The previous quarter’s EPS was -$0.83. KURA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year KURA has Performed in-line its overall industry.
Next quarter’s earnings estimate for KURA is -$0.90 with a range of -$1.02 to -$0.81. The previous quarter’s EPS was -$0.83. KURA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year KURA has Performed in-line its overall industry.

KURA Sales Forecast

Next quarter’s sales forecast for KURA is $20.16M with a range of $5.40M to $26.75M. The previous quarter’s sales results were $18.27M. KURA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year KURA has Performed in-line its overall industry.
Next quarter’s sales forecast for KURA is $20.16M with a range of $5.40M to $26.75M. The previous quarter’s sales results were $18.27M. KURA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year KURA has Performed in-line its overall industry.

KURA Stock Forecast FAQ

What is KURA’s average 12-month price target, according to analysts?
Based on analyst ratings, Kura Oncology’s 12-month average price target is 28.11.
    What is KURA’s upside potential, based on the analysts’ average price target?
    Kura Oncology has 190.40% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is KURA a Buy, Sell or Hold?
          Kura Oncology has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Kura Oncology’s price target?
            The average price target for Kura Oncology is 28.11. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $40.00 ,the lowest forecast is $15.00. The average price target represents 190.40% Increase from the current price of $9.68.
              What do analysts say about Kura Oncology?
              Kura Oncology’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of KURA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.